AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34655304 — intervention group
Group type: COMPARATOR
Intervention: Buccal mucosa graft (BMG)
Number of subjects: 100
Study 34918634 — intervention group
Group type: EXPERIMENTAL
Intervention: Core muscle strengthening exercise
Number of subjects: 40
Study 34918634 — intervention group
Group type: COMPARATOR
Intervention: General stretching exercise
Number of subjects: 40
Study 34918634 — intervention group
Group type: COMPARATOR
Intervention: Intergroup analysis
Number of subjects: 40
Study 34551581 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) - 40 ml 0.125% SB plus 20 ml of LB
Number of subjects: 78
Study 34551581 — intervention group
Group type: COMPARATOR
Intervention: Standard bupivacaine (SB) - 60 ml of 0.25% SB
Number of subjects: 78
Study 34949392 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional closure of the iASD
Number of subjects: 80
Study 34949392 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (CT)
Number of subjects: 80
Study 34949392 — intervention group
Group type: EXPERIMENTAL
Intervention: MITHRAS cohort (iASD present)
Number of subjects: 80
Study 35850363 — intervention group
Group type: EXPERIMENTAL
Intervention: NBTXR3 plus external-beam radiotherapy (EBRT) (Arm A)
Number of subjects: 179
Study 35850363 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm B)
Number of subjects: 179
Study 34165501 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT) 50 Gy
Number of subjects: 394
Study 34165501 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 394
Study 34165501 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 394
Study 35246723 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF-System implantation
Number of subjects: 554
Study 35246723 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 554
Study 36208718 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 240
Study 36208718 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WL)
Number of subjects: 240
Study 33782190 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 69
Study 33782190 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 69
Study 32379347 — intervention group
Group type: EXPERIMENTAL
Intervention: Random selection of single colonies from agar plates
Number of subjects: 0
Study 32379347 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genomic sequencing technologies
Number of subjects: 0
Study 33471484 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive specialized inflammatory bowel diseases (IBD) emergency department consultation and multidisciplinary IBD team (IBD‐MDT) intervention
Number of subjects: 45
Study 33471484 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography during hospital admission
Number of subjects: 45
Study 33471484 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions during hospital admission
Number of subjects: 45
Study 33471484 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 45
Study 35063116 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg orally twice per day for 12 months
Number of subjects: 45
Study 35063116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 35063116 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 45
Study 33733338 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg single dose
Number of subjects: 0
Study 33733338 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 300 mg single dose
Number of subjects: 0
Study 33733338 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib (both doses)
Number of subjects: 0
Study 32521287 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive e‐cigarette prevention video ads from The Real Cost campaign
Number of subjects: 543
Study 32521287 — intervention group
Group type: COMPARATOR
Intervention: Information‐only e‐cigarette harms control videos
Number of subjects: 543
Study 36448618 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless full-HD Augmented Reality Head-Mounted Display (AR-HMD)
Number of subjects: 38
Study 36448618 — intervention group
Group type: COMPARATOR
Intervention: TV Monitors (TVM)
Number of subjects: 38
Study 36448618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HMD and TVM
Number of subjects: 38
Study 32920957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortasyn Connect (125 mL once-a-day drink)
Number of subjects: 311
Study 32920957 — intervention group
Group type: COMPARATOR
Intervention: Placebo control drink (isocaloric, same tasting)
Number of subjects: 311
Study 32689756 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 48
Study 32689756 — intervention group
Group type: COMPARATOR
Intervention: Ringer's sodium lactate (Control)
Number of subjects: 48
Study 34473645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg, Trulicity)
Number of subjects: 34
Study 34473645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 34
Study 32947496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid (LA) at doses of 30, 60, or 120 mg/mL
Number of subjects: 15
Study 32947496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iohexol, 1.5 mL)
Number of subjects: 15
Study 32947496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid (LA) at doses of 60, 120 mg/mL
Number of subjects: 15
Study 35041662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (increased physical activity, weight loss target 7% through meal replacements and medication Orlistat)
Number of subjects: 379
Study 35041662 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle intervention (increased physical activity alone without targeted weight loss)
Number of subjects: 379
Study 35041662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 379
Study 35041662 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle intervention
Number of subjects: 379
Study 34925513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest-to-back skin-to-skin contact (CB SSC)
Number of subjects: 46
Study 34925513 — intervention group
Group type: COMPARATOR
Intervention: Chest-to-chest skin-to-skin contact (CC SSC)
Number of subjects: 46
Study 34447234 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of goal caloric requirements (group A)
Number of subjects: 54
Study 34447234 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of goal caloric requirements (group B)
Number of subjects: 54
Study 34447234 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of goal caloric requirements (group C)
Number of subjects: 54
Study 32278640 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention in the interventional school
Number of subjects: 398
Study 32278640 — intervention group
Group type: COMPARATOR
Intervention: Control school (no specific intervention mentioned)
Number of subjects: 398
Study 35365036 — intervention group
Group type: EXPERIMENTAL
Intervention: EPPM-STM
Number of subjects: 101
Study 33736994 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for chronic endometritis
Number of subjects: 0
Study 33736994 — intervention group
Group type: COMPARATOR
Intervention: Not including chronic endometritis in initial baseline study
Number of subjects: 0
Study 34950454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 248
Study 34950454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 36463027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage PRF (60 V)
Number of subjects: 41
Study 36463027 — intervention group
Group type: COMPARATOR
Intervention: Low-voltage PRF (45 V)
Number of subjects: 41
Study 33401239 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum Power Load Training (OPT)
Number of subjects: 20
Study 33401239 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study 33186312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremoval of the blocker at the end of the pilot tube
Number of subjects: 408
Study 33186312 — intervention group
Group type: COMPARATOR
Intervention: Removal of the blocker and actively deflating the cuff before SLMA insertion
Number of subjects: 408
Study 33220710 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy with neuromobilization (NM)
Number of subjects: 80
Study 33220710 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (care group)
Number of subjects: 80
Study 35089607 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with pomalidomide and dexamethasone (D‐Pd)
Number of subjects: 0
Study 35089607 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 0
Study 33330958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) 2 mg
Number of subjects: 54
Study 33330958 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 54
Study 33330958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) after sham re-treatment
Number of subjects: 54
Study 33330958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 54
Study 33330958 — intervention group
Group type: COMPARATOR
Intervention: Sham/IVT-AFL
Number of subjects: 54
Study 36207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at 1000-3000 mg
Number of subjects: 176
Study 36207063 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin (FPHT) at 22.5 mg/kg
Number of subjects: 176
Study 36207063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 176
Study 36207063 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin (FPHT)
Number of subjects: 176
Study 33404895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 50 μg and formoterol fumarate 6 μg via pMDI)
Number of subjects: 56
Study 33404895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 100 μg and formoterol fumarate 12 μg via pMDI)
Number of subjects: 56
Study 33404895 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF1535 (beclometasone dipropionate 200 μg and formoterol fumarate 24 μg via pMDI)
Number of subjects: 56
Study 33404895 — intervention group
Group type: COMPARATOR
Intervention: Free combination of beclometasone dipropionate and formoterol fumarate
Number of subjects: 56
Study 32865652 — intervention group
Group type: EXPERIMENTAL
Intervention: vanucizumab (experimental, E)
Number of subjects: 189
Study 32865652 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab (control, C)
Number of subjects: 189
Study 35568380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention (two 90-minute sessions, one week apart)
Number of subjects: 1636
Study 35568380 — intervention group
Group type: COMPARATOR
Intervention: Usual health education only (control)
Number of subjects: 1636
Study 34736575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2) 1 mg/day plus vaginal progesterone (P4) 45 mg/day for 10 days each month
Number of subjects: 0
Study 34736575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36282369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography group (n = 81) with assistance of right ventriculography
Number of subjects: 108
Study 36282369 — intervention group
Group type: COMPARATOR
Intervention: Non-radiography group (n = 27)
Number of subjects: 108
Study 36282369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography group (n = 81)
Number of subjects: 108
Study 33745439 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX test (20 mg, 2 × 10 mg capsules)
Number of subjects: 52
Study 33745439 — intervention group
Group type: COMPARATOR
Intervention: MTX reference (20 mg, 2 × 10 mg capsules)
Number of subjects: 52
Study 32276315 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0
Study 32276315 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0
Study 32276315 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day (placebo)
Number of subjects: 0
Study 32276315 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)
Number of subjects: 0
Study 34793832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 1195
Study 34793832 — intervention group
Group type: COMPARATOR
Intervention: Phakic controls
Number of subjects: 1195
Study 35008112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 425
Study 35008112 — intervention group
Group type: COMPARATOR
Intervention: Hot snare polypectomy (HSP)
Number of subjects: 425
Study 35008112 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP and HSP
Number of subjects: 425
Study 35008112 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP
Number of subjects: 425
Study 33464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEIs or ARBs (n=334)
Number of subjects: 659
Study 33464336 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ACEIs or ARBs (n=325)
Number of subjects: 659
Study 33464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEIs or ARBs
Number of subjects: 659
Study 33464336 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ACEIs or ARBs
Number of subjects: 659
Study 32423936 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Step exercise programme with additional monthly educational videos about healthy ageing and fall prevention
Number of subjects: 1400
Study 32423936 — intervention group
Group type: COMPARATOR
Intervention: Monthly educational videos alone
Number of subjects: 1400
Study 36207846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (Ph-D group)
Number of subjects: 7640
Study 36207846 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (Ph-I group)
Number of subjects: 7640
Study 36207846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine plus dexamethasone (group A)
Number of subjects: 7640
Study 36207846 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (group B)
Number of subjects: 7640
Study 36207846 — intervention group
Group type: EXPERIMENTAL
Intervention: CCCG-ALL-2015 protocol
Number of subjects: 7640
Study 33108582 — intervention group
Group type: COMPARATOR
Intervention: Incredible Years parenting intervention
Number of subjects: 387
Study 33108582 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 387
Study 32593173 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 µg Nasacthin003 (nasal formulation with chitosan)
Number of subjects: 60
Study 32593173 — intervention group
Group type: COMPARATOR
Intervention: 250 µg IV Synacthen
Number of subjects: 60
Study 32593173 — intervention group
Group type: EXPERIMENTAL
Intervention: salivary cortisol and cortisone
Number of subjects: 60
Study 35952956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpneumatic compression device (NPCD)
Number of subjects: 50
Study 35952956 — intervention group
Group type: COMPARATOR
Intervention: Active pneumatic compression device (APCD)
Number of subjects: 50
Study 34380842 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra epidural anesthesia (GEA group)
Number of subjects: 60
Study 34380842 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and transversus abdominis plane block analgesia (TAP group)
Number of subjects: 60
Study 33036670 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stent (SS) strategy
Number of subjects: 103
Study 33036670 — intervention group
Group type: COMPARATOR
Intervention: Double-stent (DS) strategy
Number of subjects: 103
Study 33567475 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm with rescue medication
Number of subjects: 0
Study 33567475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 35583186 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg (2.5 mg if impaired renal function or concomitant antiplatelet therapy)
Number of subjects: 1500
Study 35583186 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (vitamin K antagonist or antiplatelet therapy)
Number of subjects: 1500
Study 35583186 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1500
Study 34982433 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercises
Number of subjects: 34
Study 34982433 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 34
Study 32698430 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological treatment using SonicHand and Riablo™ systems providing auditory and visual biofeedback
Number of subjects: 0
Study 32698430 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 0
Study 32698430 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 34611057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Group (HIG)
Number of subjects: 51
Study 34611057 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Group (LIG)
Number of subjects: 51
Study 33557340 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive patients undergoing (chemo) radiotherapy
Number of subjects: 0
Study 33557340 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative patients undergoing (chemo) radiotherapy
Number of subjects: 0
Study 33807435 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique-specific high-intensity interval training (HIIT)
Number of subjects: 16
Study 33807435 — intervention group
Group type: COMPARATOR
Intervention: Traditional taekwondo training
Number of subjects: 16
Study 33059828 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN XT TAVR
Number of subjects: 0
Study 33059828 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 TAVR
Number of subjects: 0
Study 33059828 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study 35099994 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 0
Study 35099994 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic or intermediate-dose heparins
Number of subjects: 0
Study 34203925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoidan (3.0 g/day from beverages)
Number of subjects: 40
Study 34203925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (citric acid, sucralose, and caramel beverages)
Number of subjects: 40
Study 36170552 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigma condition
Number of subjects: 49
Study 36170552 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 49
Study 33970254 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise CMD prevention program, stage 1: CMD risk score completion.
Number of subjects: 0
Study 33970254 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise CMD prevention program, stage 2: Additional measurements after increased risk identification.
Number of subjects: 0
Study 35965109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.11 mg OC-02 SNS
Number of subjects: 165
Study 35965109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.55 mg OC-02 SNS
Number of subjects: 165
Study 35965109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mg OC-02 SNS
Number of subjects: 165
Study 35965109 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 165
Study 33975710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose imaging protocol (ULDP)
Number of subjects: 0
Study 35716856 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 83
Study 35716856 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 83
Study 35716856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPAP and standard care)
Number of subjects: 83
Study 32034019 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (dose-titrated from 2g to a targeted oral dose of 4g daily)
Number of subjects: 130
Study 32034019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose pills)
Number of subjects: 130
Study 32034019 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 130
Study 35995640 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with 40% rose essential oil inhalation for three consecutive nights
Number of subjects: 60
Study 35995640 — intervention group
Group type: COMPARATOR
Intervention: Distilled water inhalation as placebo
Number of subjects: 60
Study 33399384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral QLB
Number of subjects: 96
Study 33399384 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior QLB
Number of subjects: 96
Study 33399384 — intervention group
Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 96
Study 32920321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cerebellar 1 Hz deep repetitive transcranial magnetic stimulation
Number of subjects: 24
Study 32920321 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 34980596 — intervention group
Group type: EXPERIMENTAL
Intervention: P-DIPS intervention along with usual care
Number of subjects: 56
Study 34980596 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 33378243 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent-mapping condition
Number of subjects: 72
Study 33378243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (both consistent and random conditions)
Number of subjects: 72
Study 33378243 — intervention group
Group type: COMPARATOR
Intervention: Random-mapping condition
Number of subjects: 72